Heber Rew Bright Bright

Heber Rew Bright Bright

Auto-generated profile, based on publicly available information

Heber Rew Bright Bright

Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester , Manchester

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2024 in Online Journal of Public Health Informatics
Verified
Journal Article
Open access
AAAditi Apte
Aditi Apte
HBHeber Rew Bright
Heber Rew Bright
SKSandeep Kadam
Sandeep Kadam
TSThambu David Sundarsanam
Thambu David Sundarsanam
SCSujith J Chandy
Sujith J Chandy
Background: e-Pharmacy can potentially solve problems related to the quality of services and products, cost, and access to medicines in low- and middle-income countries. This review aims to understand the facilitators and barriers to the implementation of e-pharmacy in India. Objective: This scoping review aimed (1) to understand the facilitators and barriers to the use of e-pharmacy in India and (2) to estimate the potential for e-pharmacy in India for improving access to medication, improving the quality of services and medicines, and decreasing costs of medications. Methods: All published and gray literature from July 1, 2011, to June 30, 2021, relating to e-pharmacy, was searched from MEDLINE, Scopus, ProQuest, and Google using a systematic search strategy. Results: In total, 1464 titles and abstracts were screened, of which 47 full-texts were included in the review. e-Pharmacy can potentially improve access to medications for remote areas, and old and debilitated individuals. e-Pharmacies can enable lean supply chain management, lower cost, and allow easy tracking of dispensed medicines. There is potential for integration of e-pharmacy services into the national program of Bhartiya Jan Aushadhi Pariyojana. However, the country is not adequately regulated to prevent the growth of illicit e-pharmacies. Lack of global accreditation and internet coverage, digital literacy, and transnational access are other challenges. Conclusions: E-pharmacy has the potential to improve universal health coverage in India by improving access to medicines and lowering the overall cost of health care. However, future growth will need specific regulations and accreditation mechanisms. Trial Registration: Open Science Forum; https://doi.org/10.17605/OSF.IO/6R9YQ

17 September 2019 in Current Drug Safety
Verified
Journal Article
Open access
PDF file
HBHeber Rew Bright
Heber Rew Bright
SCSujith J. Chandy
Sujith J. Chandy
RCRaju Titus Chacko
Raju Titus Chacko
SBSelvamani Backianathan
Selvamani Backianathan
Background: Cisplatin is a commonly used chemotherapy agent known to induce serious adverse reactions that may require hospital readmission. We aimed to analyze the extent and factors associated with unplanned hospital admissions due to cisplatin-based chemotherapy regimen-induced adverse reactions. Methods: Retrospective review of medical records of those patients who received at least one cycle of chemotherapy with cisplatin-based regimen during a six-month period from March to August 2017. Results: Of the 458 patients who received cisplatin during the study period, 142 patients did not meet inclusion criteria. The remaining 316 patients had a total of 770 episodes of primary admissions for chemotherapy administration. Overall, 187 episodes (24%) of intercycle unplanned hospital admission were recorded of which a major proportion (n=178; 23%) was due to chemotherapy-induced adverse reactions. Underweight patients had higher odds of unplanned admission (OR 1.77, 95% confidence interval [CI] 1.11 to 1.77). Significantly, more number of patients with cancers of head and neck and cancers of musculoskeletal were readmitted (p<0.001). Compared to high-dose cisplatin, low- and intermediate-dose cisplatin had lesser odds of unplanned admission (OR 0.52 and 0.77; 95% CI, 0.31 to 0.88 and 0.41 to 1.45, respectively). Patients without concomitant radiotherapy, drug-drug interaction and initial chemotherapy cycles had lesser odds of unplanned admission (OR 0.38, 0.50 and 0.52; 95% CI, 0.26 to 0.55, 0.25 to 0.99 and 0.32 to 0.84 respectively). Unplanned admissions were mainly due to blood-related (31%) and gastrointestinal (19%) adverse reactions. Among chemotherapy regimens, cisplatin monotherapy (34%) and cisplatin with doxorubicin (20%) regimens resulted in a major proportion of unplanned admissions. Conclusion: These findings highlight risk factors that help identify high-risk patients and suggest that therapy modifications may reduce hospital readmissions due to cisplatin-based chemotherapy-induced adverse reactions.

31 October 2025 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
HBHeber Rew Bright Bright
Heber Rew Bright Bright
DPDuc Binh Phan
Duc Binh Phan
AZAmna Zahid
Amna Zahid
LALeila Motedayen Aval
Leila Motedayen Aval
SMShilpa Manupati
Shilpa Manupati
ZYZenas Z. N. Yiu
Zenas Z. N. Yiu
Introduction Systemic treatments including standard and targeted drugs for psoriasis could increase the risk of serious infections. In this study we assessed the serious infection risk associated with systemic treatments in patients with psoriasis. Methods A systematic review of randomised controlled trials (RCTs) and non-randomised studies of interventions (NRSIs) comparing systemic treatments with placebo or each other was performed. Studies included in Medline, Embase, Cochrane register, CINAHL and ClinicalTrials.gov until September 2024 were eligible if at least 50 adults or children with plaque psoriasis were studied. The primary outcome was serious infection defined as any infection resulting in hospitalization, administration of intravenous antibiotics, death or classified as serious by study authors. Two authors independently performed screening for study eligibility. A frequentist network meta-analysis (NMA) was performed using random effects model. RCT, NRSI and combined (RCT and NRSI) networks were created. Results From 119 eligible RCTs, 76 with at least one serious infection event (n = 39,044) and out of 33 eligible NRSIs, 6 without critical risk of bias (n = 306,762) were included in the NMA. Patients were predominantly male (up to 85%) with a mean age ranging from 13 to 52 years. The RCT network showed no increase in serious infection risk with any drug or drug class when compared with each other. The NRSI network showed higher risk with infliximab and adalimumab compared to several other drugs, especially infliximab vs methotrexate (IRR 2.85; 95% CI 1.48, 5.46), and adalimumab vs ustekinumab (IRR 1.51; 95% CI 1.25, 1.83). In the combined NMA, infliximab and adalimumab were additionally shown to have significantly higher risk than acitretin, bimekizumab, methotrexate, placebo, risankizumab, and secukinumab. Conclusions The tumour necrosis factor alpha (TNFα) inhibitors adalimumab and infliximab had higher risk of serious infections in the combined NMA. Our findings may inform clinicians and patients concerned about the risk of emergent serious infection on therapy.

1 June 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
HBHeber Rew Bright
Heber Rew Bright
ASAshish Singh
Ashish Singh
AJAnjana Joel
Anjana Joel
JGJosh Thomas Georgy
Josh Thomas Georgy
AJAjoy Oommen John
Ajoy Oommen John
SCSujith J. Chandy
Sujith J. Chandy
PURPOSE: We examined the efficacy of topical capsaicin in reducing delayed chemotherapy-induced nausea and vomiting (CINV). METHODS: Adults on highly emetogenic chemotherapy regimens applied 2 g of capsaicin ointment (0.075%) or matching placebo four times a day to the abdomen for 5 days in addition to standard antiemetic regimen in this blinded randomized controlled trial. Patients were monitored for nausea and vomiting in the immediate (day 1), delayed (days 2-5), and extended phases (days 2-15). Self-reported incidence and daily episodes of CINV were compared between the groups. Onset, severity, need for rescue antiemetics, cumulative vomiting episodes, and safety were also compared. RESULTS: In total, 160 patients were enrolled. The final modified intention-to-treat population included 75 patients each in the capsaicin and placebo groups. Fewer patients experienced nausea (36.0% [n = 27] v 53.3% [n = 40]; P = .033) and vomiting (28.0% [n = 21] v 42.7% [n = 32]; P = .060) in the capsaicin arm during the delayed phase. During the extended phase, there was a significantly lower incidence of nausea (44% v 64.0%; P = .014) in the capsaicin arm. No difference in nausea (26.7% v 25.3%) or vomiting (22.7% v 18.7%) was evident in the immediate phase. The average daily episodes of nausea and vomiting were significantly fewer in the capsaicin arm during the delayed and extended phases. With capsaicin, no grade 3 nausea (9.3% v 0.0%; P = .007) was observed, and the time to first nausea and vomiting was significantly prolonged. There were no differences between the groups with respect to rescue antiemetics, unscheduled hospital visits, and adverse events. CONCLUSION: Topical capsaicin reduced the incidence of nausea and the average number of vomiting episodes during delayed and extended phases without increasing adverse effects.

5 May 2026 in British Journal of Dermatology
Verified
Journal Article
Open access
HBHeber Rew Bright Bright
Heber Rew Bright Bright
CSCatherine H Smith
Catherine H Smith
PLPhilip Laws
Philip Laws
NRNick Reynolds
Nick Reynolds
DPDuc Binh Phan
Duc Binh Phan
ZYZenas Z N Yiu
Zenas Z N Yiu
Background: Systemic treatments for psoriasis could increase the risk of serious infection due to their inhibitory effect on the immune system. Objectives: To estimate and compare the serious infection risk associated with systemic treatments for psoriasis Methods: Adult patients with psoriasis who received at least one of the systemic treatments and had 6-month follow-up data recorded in the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) database were included in the analysis. Patients were followed from the time of drug initiation to drug discontinuation, death or last available follow-up date. Infections that occurred during or up to 90 days after treatment discontinuation resulting in hospitalization, the administration of intravenous antimicrobials or death were considered serious. Inverse probability of treatment weighting was used to balance baseline covariates. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were calculated using a piece-wise Cox proportional hazards model. A recurrent event analysis was also performed using the Prentice–Williams–Peterson model. Missing data were handled using multiple imputation. Results: In total, 46 770 treatment episodes from 18 976 patients were analysed. Patients were predominantly men (n = 10 893; 57.4%) and had a mean (SD) age of 45.64 (13.67) years and a mean (SD) BMI of 31.60 (7.28) kg m–2. The incidence rate of serious infections was 27.67 events per 1000 person-years (95% CI 26.72–28.65) and the rate of recurrent serious infection in those with prior infection was 78.70 events per 1000 person-years (95% CI 75.17–82.36). The piecewise Cox proportional hazards model showed an increased risk of serious infection with apremilast (HR 1.53, 95% CI 1.27–1.80) and secukinumab (HR 1.34, 95% CI 1.18–1.50) compared with adalimumab. However, these findings were not consistent across sensitivity analyses. The recurrent event analysis showed a lower risk with risankizumab than with brodalumab (HR 0.74, 95% CI 0.55–0.99), etanercept (HR 0.75, 95% CI 0.60–0.94) and standard treatments (HR 0.80, 95% CI 0.65–0.98). Serious infection-associated deaths were rare (incidence rate 1.81 per 1000 person-years, 95% CI 1.57–2.07). Conclusions: Despite isolated signals in the time-to-first event analysis, the more robust recurrent event analysis showed that risankizumab was associated with a lower risk of serious infections, while no significant differences were observed among the other systemic treatments for psoriasis.

22 July 2023 in JMIR Preprints
Verified
Preprint
Open access
AAAditi Apte
Aditi Apte
HBHeber Rew Bright
Heber Rew Bright
SKSandeep Kadam
Sandeep Kadam
TSThambu David Sundarsanam
Thambu David Sundarsanam
SCSujith J Chandy
Sujith J Chandy
BACKGROUND e-Pharmacy can potentially solve problems related to the quality of services and products, cost, and access to medicines in low- and middle-income countries. This review aims to understand the facilitators and barriers to the implementation of e-pharmacy in India. OBJECTIVE This scoping review aimed (1) to understand the facilitators and barriers to the use of e-pharmacy in India and (2) to estimate the potential for e-pharmacy in India for improving access to medication, improving the quality of services and medicines, and decreasing costs of medications. METHODS All published and gray literature from July 1, 2011, to June 30, 2021, relating to e-pharmacy, was searched from MEDLINE, Scopus, ProQuest, and Google using a systematic search strategy. RESULTS In total, 1464 titles and abstracts were screened, of which 47 full-texts were included in the review. e-Pharmacy can potentially improve access to medications for remote areas, and old and debilitated individuals. e-Pharmacies can enable lean supply chain management, lower cost, and allow easy tracking of dispensed medicines. There is potential for integration of e-pharmacy services into the national program of Bhartiya Jan Aushadhi Pariyojana. However, the country is not adequately regulated to prevent the growth of illicit e-pharmacies. Lack of global accreditation and internet coverage, digital literacy, and transnational access are other challenges. CONCLUSIONS E-pharmacy has the potential to improve universal health coverage in India by improving access to medicines and lowering the overall cost of health care. However, future growth will need specific regulations and accreditation mechanisms. CLINICALTRIAL Open Science Forum; https://doi.org/10.17605/OSF.IO/6R9YQ